Myo-inositol (PCOS)
The verdict
Widely prescribed for PCOS, but Cochrane finds no high-quality evidence backing routine use.
An insulin-sensitizing compound widely prescribed to PCOS patients before IVF or ovulation induction.
What the evidence shows
Cochrane (13 trials, 1,472 subfertile women with PCOS): no high-quality evidence supports the now-common clinical practice of prescribing it, for live birth or adverse-effect outcomes.
Evidence tier
Cochrane review (weak)🔵 A Cochrane systematic review exists; evidence is low/very-low certainty.
Sources
Take this further
Last reviewed .